ICU Medical, Inc.
ICUI · NASDAQ Global Select · USD
178,85USD
+6,74 (+3,92 %)Stand 9. Nov., 21:00
Nachbörslich178,850,00 (0,00 %)19:30 ET
Kennzahlen
- Eröffnung
- 173,90
- Vortag
- 172,11
- Tagesspanne
- 172,15 – 181,29
- 52 Wochen
- 113,37 – 192,85
- Volumen
- 344.709
- Ø Volumen
- 274.091
- Börsenwert
- 4,47 Mrd. $
- KGV
- 74,2
- Gewinn je Aktie (TTM)
- 2,39
- Dividendenrendite
- 0,0 %
- Beta
- 0,8
- Nächste Zahlen
- 18. Feb. 2027
Finanzen
| USD | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Umsatz | 2,23 Mrd. | 2,38 Mrd. | 2,26 Mrd. | 2,28 Mrd. | 1,32 Mrd. |
| Herstellungskosten | 1,41 Mrd. | 1,56 Mrd. | 1,52 Mrd. | 1,58 Mrd. | 824,82 Mio. |
| Bruttogewinn | 819,66 Mio. | 824,78 Mio. | 739,87 Mio. | 697,76 Mio. | 491,49 Mio. |
| Forschung und Entwicklung | 87,5 Mio. | 88,62 Mio. | 85,34 Mio. | 92,98 Mio. | 47,5 Mio. |
| Vertrieb und Verwaltung | 625,21 Mio. | 638,76 Mio. | 606,69 Mio. | 608,35 Mio. | 302,58 Mio. |
| Operatives Ergebnis | 106,95 Mio. | 42,96 Mio. | 22,83 Mio. | −42,9 Mio. | 123,25 Mio. |
| EBITDA | 309,29 Mio. | 260,04 Mio. | 253,2 Mio. | 191,55 Mio. | 213,86 Mio. |
| Nettogewinn | 732.000 | −117,69 Mio. | −29,66 Mio. | −74,29 Mio. | 103,14 Mio. |
| Gewinn je Aktie (verwässert) | 0,03 | -4,83 | -1,23 | -3,11 | 4,74 |
Umsatz nach Segment
Produkte · FY 2025
- Equipment revenue74,84 Mio. $69,69 %
- Software revenue31,37 Mio. $29,22 %
- Other deferred revenue1,18 Mio. $1,10 %
Anteil · ggü. Vorjahr (FY 2024)
Regionen · FY 2025
- UNITED STATES1,36 Mrd. $60,78 %−11,49 %
- EMEA411,68 Mio. $18,45 %+4,61 %
- Asia Pacific232,9 Mio. $10,44 %+0,39 %
- Other foreign countries230,56 Mio. $10,33 %+3,12 %
Anteil · ggü. Vorjahr (FY 2024)
Bewertung
Letzte 12 Monate
- KGV
- 74,2
- Kurs-Umsatz-Verhältnis
- 2,0
- Kurs-Buchwert-Verhältnis
- 2,0
- PEG
- 0,0
- Bruttomarge
- 38,7 %
- Operative Marge
- 6,8 %
- Nettomarge
- 2,8 %
- Verschuldungsgrad
- 0,5
- EV/EBITDA
- 18,7
- Eigenkapitalrendite
- 2,8 %
- Kapitalrendite (ROIC)
- 4,3 %
- Free-Cashflow-Rendite
- 4,7 %
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Bruttomarge | 36,8 % | 34,6 % | 32,8 % | 30,6 % | 37,3 % |
| Operative Marge | 4,8 % | 1,8 % | 1,0 % | −1,9 % | 9,4 % |
| Nettomarge | 0,0 % | −4,9 % | −1,3 % | −3,3 % | 7,8 % |
| KGV | 4.803,7 | -32,1 | -81,1 | -50,6 | 48,8 |
| Kurs-Umsatz-Verhältnis | 1,6 | 1,6 | 1,1 | 1,6 | 3,8 |
| Kurs-Buchwert-Verhältnis | 1,7 | 1,9 | 1,1 | 1,8 | 3,1 |
| Verschuldungsgrad | 0,7 | 0,8 | 0,8 | 0,8 | 0,0 |
| Liquidität 3. Grades | 2,4 | 2,6 | 2,5 | 2,5 | 5,1 |
| Dividendenrendite | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Unternehmenswert | 4,6 Mrd. | 5,12 Mrd. | 3,85 Mrd. | 5,28 Mrd. | 4,53 Mrd. |
| EV/EBITDA | 14,9 | 19,7 | 15,2 | 27,6 | 21,2 |
| Eigenkapitalrendite | 0,0 % | −6,0 % | −1,4 % | −3,6 % | 6,4 % |
| Kapitalrendite (ROIC) | 0,7 % | 1,2 % | 0,2 % | −0,7 % | 6,1 % |
| Free-Cashflow-Rendite | 2,6 % | 3,3 % | 3,0 % | −4,3 % | 3,7 % |
Wachstum
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Umsatz | −6,4 % | +5,4 % | −0,9 % | +73,2 % | +3,6 % |
| Bruttogewinn | −0,6 % | +11,5 % | +6,0 % | +42,0 % | +6,5 % |
| Operatives Ergebnis | +148,9 % | +88,2 % | +153,2 % | −134,8 % | +25,6 % |
| Nettogewinn | +100,6 % | −296,9 % | +60,1 % | −172,0 % | +18,7 % |
| Gewinn je Aktie | +100,6 % | −292,7 % | +60,5 % | −165,6 % | +17,9 % |
| Freier Cashflow | −26,4 % | +71,9 % | +144,9 % | −186,6 % | +52,3 % |
| Dividende je Aktie | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
Analysten
Einstufungen · Buy
- 1Stark kaufen
- 10Kaufen
- 1Halten
- 0Verkaufen
- 0Stark verkaufen
Kursziel
192,25
Durchschnitt · +7,49 %
Schätzungen
| FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|
| Umsatz (Ø) | 2,19 Mrd. | 2,28 Mrd. | 2,37 Mrd. |
| Umsatz (Tief – Hoch) | 2,17 Mrd. – 2,21 Mrd. | 2,26 Mrd. – 2,32 Mrd. | 2,33 Mrd. – 2,46 Mrd. |
| Gewinn je Aktie (Ø) | 8,74 | 9,67 | 10,40 |
| Gewinn je Aktie (Tief – Hoch) | 8,70 – 8,80 | 9,45 – 10,05 | 7,11 – 13,24 |
| Analysten | 5 | 5 | 3 |
Letzte Änderungen
- Piper Sandler6. Nov. 2026Overweight
- Keybanc6. Nov. 2026Overweight
- Piper Sandler7. Aug. 2026Overweight
- Needham7. Aug. 2026Buy
- BTIG7. Aug. 2026Buy
- Keybanc21. Juli 2026Overweight
- Needham27. Mai 2026Hold → Buy
- Keybanc27. Apr. 2026Overweight
Quartalszahlen
Nächste Zahlen: 18. Feb. 2027| Nov. 2026 | Aug. 2026 | Mai 2026 | Feb. 2026 | Nov. 2025 | Aug. 2025 | Mai 2025 | Feb. 2025 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | 2,14 | 1,91 | 1,78 | 1,68 | 1,43 | 1,44 | 1,23 | 1,48 |
| Gewinn je Aktie · Tatsächlich | 2,44 | 2,37 | 1,97 | 1,91 | 2,03 | 2,10 | 1,72 | 2,11 |
| Abweichung | +14,02 % | +24,08 % | +10,67 % | +13,69 % | +41,96 % | +45,83 % | +39,84 % | +42,57 % |
| Umsatz · Tatsächlich | 560,44 Mio. | 547,88 Mio. | 525,77 Mio. | 535,94 Mio. | 536,99 Mio. | 548,87 Mio. | 604,7 Mio. | 629,81 Mio. |
Dividenden und Splits
Keine Dividenden gezahlt.
Aktiensplits
- 18. März 20023:2
- 1. Apr. 19933:2
Eigentümer
Institutionen
Q2 2026 · 13F
- Anteil institutioneller Investoren
- 105,52 %
- Investoren mit 13F-Meldung
- 295
Größte Investoren
- BLACKROCK, INC.15,01 %3,75 Mio.
- JUPITER TOPCO LLC11,13 %2,78 Mio.
- VANGUARD PORTFOLIO MANAGEMENT LLC5,88 %1,47 Mio.
- FULLER & THALER ASSET MANAGEMENT, INC.5,19 %1,3 Mio.
- VANGUARD CAPITAL MANAGEMENT LLC4,49 %1,12 Mio.
- DIMENSIONAL FUND ADVISORS LP4,21 %1,05 Mio.
- STATE STREET CORP4,14 %1,02 Mio.
- SCHRODER INVESTMENT MANAGEMENT GROUP2,96 %739.138
Insider-Geschäfte
- Sanzone Virginia Ruth3. Sept. 2026 · officer: VP, General CounselVerkauf2202 Aktien · 167,67
- Sanzone Virginia Ruth3. Sept. 2026 · officer: VP, General CounselVerkauf1238 Aktien · 168,44
- Sanzone Virginia Ruth3. Sept. 2026 · officer: VP, General CounselVerkauf724 Aktien · 169,53
- Sanzone Virginia Ruth3. Sept. 2026 · officer: VP, General CounselVerkauf692 Aktien · 171,52
- Bonnell Brian Michael1. Sept. 2026 · officer: Chief Financial OfficerVerkauf6381 Aktien · 175,00
- Bonnell Brian Michael31. Aug. 2026 · officer: Chief Financial OfficerVerkauf1712 Aktien · 171,05
- Bonnell Brian Michael31. Aug. 2026 · officer: Chief Financial OfficerVerkauf1914 Aktien · 172,12
- Bonnell Brian Michael31. Aug. 2026 · officer: Chief Financial OfficerVerkauf4568 Aktien · 173,44
Vergleichbare Unternehmen
Über das Unternehmen
ICU Medical, Inc., operating globally through its subsidiaries, is a medical technology firm that specializes in the development, manufacture, and sale of devices for both infusion therapy and critical care. Their extensive product line for infusion therapy encompasses: Needlefree Connectors: Such as the MicroClave, MicroClave Clear, and NanoClave brands. Catheter Maintenance & Disinfection: Including Neutron patency devices and SwabCap/SwabTip disinfecting caps. Hemodialysis Solutions: Like Tego connectors and ClearGuard HD antimicrobial caps. Hazardous Drug Handling: With closed system transfer devices (ChemoClave, ChemoLock) and the Diana compounding system for safe preparation. They also provide a comprehensive range of intravenous (IV) solutions, diluents, and irrigation fluids, available in diverse packaging options like flexible containers and pour bottles. These include common formulations such as sodium chloride, dextrose, balanced electrolytes, lactated ringer's, mannitol, and sterile water, alongside specialized irrigation solutions like acetic acid and glycine. In medication management, ICU Medical offers sophisticated infusion pumps, including the Plum 360 and LifeCare PCA brands. Its advanced ICU Medical MedNet software enhances medication safety by integrating smart pumps with hospital electronic health records (EHRs), asset tracking, and alarm notification platforms. Accompanying professional services are also provided. For critical care environments, their portfolio features: Hemodynamic Monitoring: Systems like Cogent 2-in-1 and CardioFlo. Cardiac Output & Oximetry: TDQ, OptiQ, and TriOx catheters. Blood Pressure Transducers: Such as Transpac. Blood Sampling Systems: Including the SafeSet closed blood sampling and conservation systems. The company distributes its products to a wide spectrum of healthcare providers, including acute care hospitals, wholesalers, ambulatory clinics, and various alternate site facilities such as outpatient clinics, home healthcare services, and long-term care centers. Established in 1984, ICU Medical maintains its headquarters in San Clemente, California.
Führung
- Vivek JainChief Executive Officer & Chairman of the Board
- Christian VoigtlanderChief Operating Officer
- Brian Michael BonnellChief Financial Officer & Treasurer
- Virginia Ruth SanzoneCorporate Vice President, General Counsel, Secretary & Compliance Officer
- Daniel WoolsonPresident
- Olivia BarrallVice President of Human Resources
- CEO
- Vivek Jain
- Mitarbeitende
- 13.000
- Hauptsitz
- San Clemente, CA, US
- Sektor
- Healthcare
- Branche
- Medical - Instruments & Supplies
- Börsengang
- 31. März 1992
- Website
- icumed.com
Nachrichten
- GlobeNewsWire · 6. Nov., 8:30ICU Medical to Present at the 2026 Jefferies Global Healthcare Conference in London
- MarketBeat · 5. Nov., 21:15ICU Medical Q3 Earnings Call Highlights
- Zacks Investment Research · 5. Nov., 21:01ICU Medical (ICUI) Beats Q3 Earnings and Revenue Estimates
- Zacks Investment Research · 5. Nov., 20:31ICU Medical (ICUI) Reports Q3 Earnings: What Key Metrics Have to Say
- Seeking Alpha · 5. Nov., 18:54ICU Medical, Inc. (ICUI) Q3 2026 Earnings Call Transcript
- GlobeNewsWire · 5. Nov., 16:05ICU Medical Announces Third Quarter 2026 Results and Reaffirms Fiscal Year 2026 Guidance, Expecting Results at the High End of Range
- GlobeNewsWire · 22. Okt., 8:30ICU Medical Announces Time of Third Quarter 2026 Earnings Conference Call
- Defense World · 22. Okt., 2:45Head-To-Head Review: ICU Medical (NASDAQ:ICUI) & Beta Bionics (NASDAQ:BBNX)
- Zacks Investment Research · 9. Okt., 10:363 Medical Product Stocks Positioned to Ride on the Industry Tailwinds
- Defense World · 5. Okt., 4:28ICU Medical, Inc. (NASDAQ:ICUI) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.